Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60

Benzinga · 3d ago
Leerink Partners analyst Joseph Schwartz downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform and lowers the price target from $82 to $60.